1lhe › Citations

Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.

Weber PC, Lee SL, Lewandowski FA, Schadt MC, Chang CW, Kettner CA
Biochemistry 34 3750-7 (1995)
Related entries: 1lhc, 1lhd, 1lhf, 1lhg

Cited: 33 times
EuropePMC logo PMID: 7893672

Abstract

The X-ray crystallographic structure of Ac-(D)Phe-Pro-boroArg-OH [DuP714, Ki = 0.04 nM; Kettner, C., Mersinger, L., & Knabb, R. (1990) J. Biol. Chem. 265, 18289] complexed with human alpha-thrombin shows the boron atom covalently bonded to the side-chain oxygen of the active site serine, Ser195. The boron adopts a nearly tetrahedral geometry, and the boronic acid forms a set of interactions with the protein that mimic the tetrahedral transition state of serine proteases. Contributions of the arginine side chain to inhibitor affinity were examined by synthesis of the ornithine, lysine, homolysine, and amidine analogs of DuP714. The basic groups interact with backbone carbonyl groups, water molecules, and an aspartic acid side chain (Asp189) located in the thrombin S1 specificity pocket. The variation in inhibition constant by 3 orders of magnitude appears to reflect differences in the energetics of interactions made with thrombin and differences in ligand flexibility in solution.(ABSTRACT TRUNCATED AT 250 WORDS)

Articles - 1lhe mentioned but not cited (1)

  1. Diversity-guided Lamarckian random drift particle swarm optimization for flexible ligand docking. Li C, Sun J, Palade V. BMC Bioinformatics 21 286 (2020)


Reviews citing this publication (10)

  1. The development of proteasome inhibitors as anticancer drugs. Adams J. Cancer Cell 5 417-421 (2004)
  2. Progress in the design of low molecular weight thrombin inhibitors. Srivastava S, Goswami LN, Dikshit DK. Med Res Rev 25 66-92 (2005)
  3. Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors. Touchet S, Carreaux F, Carboni B, Bouillon A, Boucher JL. Chem Soc Rev 40 3895-3914 (2011)
  4. Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. Salemme FR, Spurlino J, Bone R. Structure 5 319-324 (1997)
  5. Boron therapeutics on the horizon. Groziak MP. Am J Ther 8 321-328 (2001)
  6. New thrombin inhibitors in cardiovascular disease. Ripka WC. Curr Opin Chem Biol 1 242-253 (1997)
  7. Cardiovascular chemotherapy: anticoagulants. Shafer JA. Curr Opin Chem Biol 2 458-465 (1998)
  8. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Expert Rev Anticancer Ther 5 465-476 (2005)
  9. [Molecular similarity. 2. The structural basis of drug design] Kubinyi H. Pharm Unserer Zeit 27 158-172 (1998)
  10. Proteinase inhibitors and activators strategic targets for therapeutic intervention. Deadman J. J. Pept. Sci. 6 421-431 (2000)

Articles citing this publication (22)

  1. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Groll M, Berkers CR, Ploegh HL, Ovaa H. Structure 14 451-456 (2006)
  2. The molecular environment of the Na+ binding site of thrombin. Zhang E, Tulinsky A. Biophys. Chem. 63 185-200 (1997)
  3. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. Zhang E, St Charles R, Tulinsky A. J. Mol. Biol. 285 2089-2104 (1999)
  4. Relating structure to thermodynamics: the crystal structures and binding affinity of eight OppA-peptide complexes. Davies TG, Hubbard RE, Tame JR. Protein Sci. 8 1432-1444 (1999)
  5. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Katz BA, Liu B, Barnes M, Springman EB. Protein Sci. 7 875-885 (1998)
  6. Computational combinatorial ligand design: application to human alpha-thrombin. Caflisch A. J. Comput. Aided Mol. Des. 10 372-396 (1996)
  7. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. Engel M, Hoffmann T, Manhart S, Heiser U, Chambre S, Huber R, Demuth HU, Bode W. J. Mol. Biol. 355 768-783 (2006)
  8. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa. Lazarova TI, Jin L, Rynkiewicz M, Gorga JC, Bibbins F, Meyers HV, Babine R, Strickler J. Bioorg. Med. Chem. Lett. 16 5022-5027 (2006)
  9. The influence of residue 190 in the S1 site of trypsin-like serine proteases on substrate selectivity is universally conserved. Sichler K, Hopfner KP, Kopetzki E, Huber R, Bode W, Brandstetter H. FEBS Lett. 530 220-224 (2002)
  10. Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090. Malley MF, Tabernero L, Chang CY, Ohringer SL, Roberts DG, Das J, Sack JS. Protein Sci. 5 221-228 (1996)
  11. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin. Féthière J, Tsuda Y, Coulombe R, Konishi Y, Cygler M. Protein Sci. 5 1174-1183 (1996)
  12. Functionality map analysis of the active site cleft of human thrombin. Grootenhuis PD, Karplus M. J. Comput. Aided Mol. Des. 10 1-10 (1996)
  13. Photoswitch inhibitors of alpha-chymotrypsin--increased substitution and peptidic character in peptidomimetic boronate esters. Pearson D, Abell AD. Org. Biomol. Chem. 4 3618-3625 (2006)
  14. Upgrading a natural product: inhibition of human beta-tryptase by cyclotheonamide analogues. Schaschke N, Sommerhoff CP. ChemMedChem 5 367-370 (2010)
  15. Atomic structures of two nitroxide spin labels complexed with human thrombin: comparison with solution studies. Nienaber VL, Berliner LJ. J Protein Chem 19 129-137 (2000)
  16. Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors. Dominguez C, Duffy DE, Han Q, Alexander RS, Galemmo RA, Park JM, Wong PC, Amparo EC, Knabb RM, Luettgen J, Wexler RR. Bioorg. Med. Chem. Lett. 9 925-930 (1999)
  17. Thrombin inhibitor design: X-ray and solution studies provide a novel P1 determinant. Nienaber VL, Boxrud PD, Berliner LJ. J Protein Chem 19 327-333 (2000)
  18. A Statistical Survey on the Binding Constants of Covalently Bound Protein-Ligand Complexes. Li X, Liu Z, Li Y, Li J, Li J, Wang R. Mol Inform 29 87-96 (2010)
  19. Inhibition of dipeptidyl peptidase IV (CD26) by peptide boronic acid dipeptides. Pargellis CA, Campbell SJ, Pav S, Graham ET, Pitner TP. J. Enzym. Inhib. 11 151-169 (1997)
  20. Heparin enhances the catalytic activity of des-ETW-thrombin. Goodwin CA, Deadman JJ, Le Bonniec BF, Elgendy S, Kakkar VV, Scully MF. Biochem. J. 315 ( Pt 1) 77-83 (1996)
  21. Novel inhibitors and activity-based probes targeting serine proteases. Ferguson TEG, Reihill JA, Martin SL, Walker B. Front Chem 10 1006618 (2022)
  22. Visualization of Topological Pharmacophore Space with Graph Edit Distance. Nakano H, Miyao T. ACS Omega 7 14057-14068 (2022)


Quick links